Floatz logo

ETOPOSIDE

Myelodysplastic Syndrome With Isolated Del(5q)

Fred Hutchinson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myelodysplastic Syndrome With Isolated Del(5q) cohort.

Asset / SponsorPhaseRating
Cediranib
Mayo Clinic
Phase 3BB
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
Mayo Clinic
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 3BB
TACROLIMUS
National Cancer Institute (NCI)
Phase 3BB

View all 22 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →